scispace - formally typeset
S

Svetlana Kotliarova

Researcher at National Institutes of Health

Publications -  27
Citations -  4456

Svetlana Kotliarova is an academic researcher from National Institutes of Health. The author has contributed to research in topics: DNA methylation & Glioma. The author has an hindex of 22, co-authored 27 publications receiving 4184 citations. Previous affiliations of Svetlana Kotliarova include RIKEN Brain Science Institute & University of Tokyo.

Papers
More filters
Journal ArticleDOI

Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.

TL;DR: Significant phenotypic and genotypic differences are demonstrated between primary human tumor-derived TSCs and their matched glioma cell lines, suggesting that TSC's may be a more reliable model than many commonly utilized cancer cell lines for understanding the biology of primary human tumors.
Journal ArticleDOI

Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells.

TL;DR: It is demonstrated that both bone morphogenetic protein (BMP)-mediated and ciliary neurotrophic factor (CNTF)-mediated Jak/STAT-dependent astroglial differentiation is impaired due to EZH2-dependent epigenetic silencing of BMP receptor 1B (BMPR1B) in a subset of glioblastoma TICs.
Journal ArticleDOI

Co-chaperone CHIP Associates with Expanded Polyglutamine Protein and Promotes Their Degradation by Proteasomes

TL;DR: It is demonstrated that CHIP (C terminus of Hsp70-interacting protein) co-immunoprecipitates with the polyglutamine-expanded huntingtin or ataxin-3 and associates with their aggregates and suppressive effect is more prominent when CHIP is overexpressed along with Hsc70.
Journal ArticleDOI

Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-κB, and glucose regulation

TL;DR: It is shown that multiple small molecular inhibitors of GSK3 activity and genetic down-regulation of G SK3alpha/beta significantly inhibit glioma cell survival and clonogenicity and may be an important therapeutic target for gliomas.
Journal ArticleDOI

Ataxin-3, the MJD1 gene product, interacts with the two human homologs of yeast DNA repair protein RAD23, HHR23A and HHR23B

TL;DR: The results suggest that this interaction is associated with the normal function of ataxin-3 and that some functional abnormality of the HHR23 proteins might exist in MJD.